OXT and obesity due to melanocortin 4 receptor deficiency: Naltrexone is an opioid antagonist with selective preference for μ-opioid receptor binding that has shown to be an effective treatment for adult obesity (Kulak-Bejda et al., 2021); μ-opioid receptor antagonism has shown to potentiate the effects of oxytocin (Nisbett et al., 2024) and increase plasma oxytocin concentrations by disinhibition of central oxytocin release in rodents during late pregnancy (Douglas et al., 1993).